Fluidigm Co. (FLDM) Stake Increased by BlackRock Inc.
BlackRock Inc. grew its stake in shares of Fluidigm Co. (NASDAQ:FLDM) by 9.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,139,878 shares of the medical research company’s stock after purchasing an additional 178,429 shares during the quarter. BlackRock Inc. owned approximately 0.05% of Fluidigm worth $18,445,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Quantamental Technologies LLC purchased a new stake in Fluidigm in the fourth quarter worth about $61,000. Rhumbline Advisers lifted its stake in Fluidigm by 42.9% in the fourth quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock worth $297,000 after acquiring an additional 10,358 shares during the period. Chicago Equity Partners LLC purchased a new stake in Fluidigm in the fourth quarter worth about $313,000. Monarch Partners Asset Management LLC purchased a new stake in Fluidigm in the fourth quarter worth about $317,000. Finally, Algert Global LLC purchased a new stake in Fluidigm in the fourth quarter worth about $483,000. 71.66% of the stock is owned by hedge funds and other institutional investors.
FLDM opened at $13.65 on Tuesday. Fluidigm Co. has a 52-week low of $4.65 and a 52-week high of $14.90. The company has a debt-to-equity ratio of 2.39, a quick ratio of 3.04 and a current ratio of 3.38. The stock has a market cap of $941.71 million, a PE ratio of -17.06 and a beta of 2.43.
FLDM has been the subject of a number of recent research reports. BidaskClub downgraded shares of Fluidigm from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. Zacks Investment Research downgraded shares of Fluidigm from a “hold” rating to a “strong sell” rating in a report on Friday, February 8th. BTIG Research initiated coverage on shares of Fluidigm in a report on Wednesday, March 13th. They issued a “buy” rating and a $15.00 target price for the company. Janney Montgomery Scott upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a report on Thursday, January 3rd. Finally, Piper Jaffray Companies boosted their target price on shares of Fluidigm from $10.00 to $14.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.00.
ILLEGAL ACTIVITY WARNING: “Fluidigm Co. (FLDM) Stake Increased by BlackRock Inc.” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dailypolitical.com/2019/04/16/fluidigm-co-fldm-stake-increased-by-blackrock-inc.html.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Further Reading: Why do companies pay special dividends?
Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.